Skip to main content
Innoviva, Inc. logo

Innoviva, Inc. — Investor Relations & Filings

Ticker · INVA ISIN · US45781M1018 LEI · 549300ACOX4QTBES6535 US Financial and insurance activities
Open in API
Filings indexed 1,226 across all filing types
Latest filing 2014-09-18 Capital/Financing Update
Country US United States of America
Listing US INVA

About Innoviva, Inc.

https://www.inva.com/

Innoviva, Inc. is a diversified holding company that manages a portfolio of royalty-generating assets and operates a commercial-stage biopharmaceutical platform. The company's core royalty business is centered on respiratory therapies, providing a stable cash flow. Through its subsidiary, Innoviva Specialty Therapeutics, it focuses on developing and commercializing innovative treatments for patients in critical care and with infectious diseases. Innoviva's strategy involves leveraging its financial assets to invest in healthcare opportunities with high unmet medical needs, aiming to advance differentiated therapies and build a diverse portfolio of healthcare assets.

Recent filings

Filing Released Lang Actions
8-K
Capital/Financing Update Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce major events. The content specifically discusses an adjustment to the conversion rate of the company's convertible promissory notes due to a dividend payment. This is an update related to the company's capital structure and financing terms. The document is short (3234 characters) and does not contain financial statements or detailed financial analysis, but rather a specific financing-related update. Therefore, it fits best under the category 'Capital/Financing Update (CAP)'.
2014-09-18 English
8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce unscheduled material events or corporate changes. The text references an event on September 7, 2014, where clinical study posters were presented at a medical congress. The document includes exhibits of study posters and pharmacokinetic analyses, but does not contain comprehensive financial statements or detailed financial performance data. It is not an annual or quarterly report, nor an earnings release. The content is primarily an announcement of clinical study results and related exhibits, typical of an 8-K filing reporting other events. Therefore, the filing type is Regulatory Filings (RNS), which is the fallback category for miscellaneous filings that do not fit other specific categories.
2014-09-08 English
THERAVANCE, INC. 8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filing, which is a current report pursuant to the Securities Exchange Act of 1934. It announces a commercial event: the launch of a pharmaceutical product (ANORO ELLIPTA) in Japan by GlaxoSmithKline and Theravance, and mentions a milestone payment obligation. There are no financial statements, quarterly or annual results, or detailed financial data. The document is short (2926 characters) and focuses on a specific event rather than a report or presentation. This fits the category of a Regulatory Filing (RNS), which is a general regulatory announcement that does not fit into more specific categories like earnings release or capital update.
2014-09-04 English
THERAVANCE, INC. 8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce unscheduled material events or corporate changes. The text includes a Regulation FD Disclosure about upcoming presentations of clinical study data at a conference, with no financial statements or detailed financial analysis. The document is relatively short (3374 characters) and serves as an announcement rather than a full report. It does not fit categories like Annual Report, Earnings Release, or Interim Report. It is not a certification or insider transaction report. Therefore, the best classification is Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2014-09-02 English
FORM 4 -
Director's Dealing
2014-08-22 English
FORM 4 -
Director's Dealing
2014-08-22 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.